Adium México
Adium México (legal entity Asofarma de México, S.A. de C.V.) is a pharmaceutical laboratory that develops, manufactures, and distributes branded prescription medications across 15 therapeutic areas, serving healthcare professionals and patients in Mexico as part of Grupo Adium, a Latin American pharmaceutical group operating in 18 countries.
- Company typePrivate
- Founded1974
- HeadquartersMéxico, Colombia
- Headcount501–1,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Adium México does
Adium México (legal entity Asofarma de México, S.A. de C.V.) is a Mexico-based pharmaceutical laboratory that develops, manufactures, and commercializes branded prescription medications across 15 therapeutic areas, including cardiology, diabetes, oncology, neurology, rare diseases, immunology, gastroenterology, gynecology, psychiatry, and urology. The company operates as the Mexican subsidiary of Grupo Adium, a Latin American pharmaceutical conglomerate with presence in 18 countries, 7,000+ collaborators, and five GMP-certified manufacturing plants in Argentina, Paraguay, Brazil, Mexico, and Uruguay producing 120+ million units annually. Grupo Adium is recognized as the sixth-largest pharmaceutical company in Latin America. Adium México also operates Adium Pro, a wholly-owned digital platform providing medical-scientific courses, clinical cases, webinars, and events to healthcare professionals.
The company pursues a dual business model: (1) proprietary and branded pharmaceutical product sales, including combination therapies and branded generics such as Tavor CR, Vesicare, Iltux, Tafirol, and Vartalon Compositum, distributed through authorized pharmacies and healthcare institutions; and (2) long-term licensing and distribution agreements with more than 10 multinational biotech and innovation companies (PharmaMar, Y-mAbs, BeiGene, Jazz Pharmaceuticals, Astellas Pharma, Debiopharm, and others), positioning Adium as the partner of choice for foreign innovators seeking pan-Latin American market access. Go-to-market is enterprise field sales via a specialized sales force targeting healthcare professionals and institutions, supported by a restricted-access healthcare professional portal, medical congresses, email marketing, and organic social channels. Manufacturing is governed by Quality by Design, GMP/GLP/GDP practices, and a pharmacovigilance system aligned with EMA and USFDA guidelines. In May 2024, the Mexican entity rebranded from Asofarma de México to Adium México to align with the broader Grupo Adium brand; the legal entity and operations remained unchanged.
Adium México firmographics
Firmographics- Name
- Adium México
- Legal name
- Asofarma de México, S.A. de C.V.
- Website
- https://adium.com.mx
- Company type
- Private
- Founded year
- 1974
- Operating status
- Operating
- Headcount range
- 501–1,000 employees
- Short description
- Adium México (legal entity Asofarma de México, S.A. de C.V.) is a pharmaceutical laboratory that develops, manufactures, and distributes branded prescription medications across 15 therapeutic areas, serving healthcare professionals and patients in Mexico as part of Grupo Adium, a Latin American pharmaceutical group operating in 18 countries.
- Ownership category
- akta.pro rank
Adium México industry classification
Industry- Product category
- Pharmaceutical Manufacturing
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Drugs and Druggists' Sundries Merchant Wholesalers (424210)
- SIC
- Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- Prescription Pharmaceutical (Rx) Wholesale Distribution (CRAOAHAA)
Keywords
Where Adium México is headquartered
LocationHeadquarters
- HQ city
- México
- HQ country
- Colombia
- HQ region
- Latin America
Offices3 records
Markets served
Adium México business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Personnel, Marketing or Sales, Technology or R&D, Supply Chain
Revenue model
- Pharmaceutical Product Sales: Sale of proprietary and licensed pharmaceutical products across multiple therapeutic areas including cardiology, diabetes, oncology, and rare diseases
- Licensing and Distribution: Licensing agreements with global biotech and innovation companies for promotion and distribution of their products throughout Latin America
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Other | Prescription pharmaceutical products |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels7 records
Adium México product offering
Product offeringCore offering
Adium México is a pharmaceutical laboratory that develops, manufactures, and commercializes a broad portfolio of prescription medications across 15 therapeutic areas including cardiology, diabetes, oncology, rare diseases, neurology, and gynecology. The company distributes both proprietary products and those licensed from global biotech partners to healthcare professionals and institutions in Mexico, supported by a specialized sales force, GMP-certified manufacturing, and pharmacovigilance systems aligned with international regulatory standards.
Product overview
Adium México is a pharmaceutical laboratory offering a broad portfolio of therapeutic products organized across 15 therapeutic areas: Cardiology, Diabetes, Analgesia, Rare Diseases, Gastroenterology, Gynecology, Hematology, Immunology, Neurology, Obesity, Oncology, Osteoarticular, Osteoporosis, Psychiatry, and Urology. The company also operates Adium Pro, a digital platform for medical-scientific content. Products include both branded medications (Tavor CR, Vesicare, Iltux, Tafirol, Vartalon, etc.) and combination therapies. The portfolio spans over 50 years of experience, offering innovative and high-quality therapeutic solutions to physicians and patients in Mexico and Latin America.
Differentiator
Problem solved
Functional benefit
Products and services
- Cardiology Portfolio Pharmaceutical products for the treatment of hypertension, hypercholesterolemia, and anticoagulation, addressing cardiovascular disease as a leading cause of death in Latin America. Prescribed by cardiology specialists.
- Diabetes Portfolio Products for treatment of Diabetes Type I and Type II, addressing a leading cause of death and disability in Latin America. Includes combination therapies such as Vidagliptina/Metformina.
- Oncology Portfolio Broad portfolio of medications for different types of cancer affecting lung, breast, pancreas, and bile ducts, including tamoxifen-based therapy. Distributed through licensing partnerships with global biotech companies.
- Rare Diseases Portfolio Medicines for rare diseases such as paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, cystic fibrosis, and idiopathic pulmonary fibrosis.
- Adium Pro Medical-scientific content platform for healthcare professionals providing access to courses, articles, clinical cases, events, webinars, and continuing medical education resources.
- Licensing and Distribution Partnerships Long-term licensing and distribution agreements with over 10 multinational biotech and innovation companies including PharmaMar, Y-mAbs, BeiGene, Jazz Pharmaceuticals, Astellas Pharma, and Debiopharm, enabling promotion and distribution of their innovative products across Latin America.
Quantifiable outcome
- 42% of waste recycled in 2023
- +3 more outcomes
Companies that use Adium México
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles2 records
Adium México technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration2 records
Feature3 records
Adium México partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core.
- PharmaMarcoreLicensing agreement for innovative pharmaceutical products, enabling distribution of advanced therapies in Latin America through Adium's regional presence and commercial capabilities.
- Y-mAbscoreLicensing partnership for pediatric oncology and other specialty therapeutic areas, leveraging Adium's regional commercial infrastructure.
- BeiGenecoreGlobal biotech partnership for innovative oncology treatments, distributed through Adium's commercial network across Latin America.
- Jazz PharmaceuticalscoreLicensing partnership for specialty pharmaceuticals, utilizing Adium's market access expertise and regulatory capabilities in the region.
- Astellas PharmacorePartnership for innovative pharmaceutical products, leveraging Adium's regional presence and specialized sales force.
- DebiopharmcoreLicensing partnership for specialty therapeutics, distributed through Adium's established commercial channels in Latin America.
- Additional Global Innovation PartnerscoreAdium holds long-term licensing agreements with more than 10 multinational innovation companies, positioning the company as the partner of choice for pharmaceutical expansion into Latin America.
Scale indicators7 records
Recent moves6 records
Expansion highlights6 records
Adium México competitors and assessment
Company assessmentBroad incumbents
- Sanofi: Sanofi is a global pharmaceutical incumbent operating in cardiovascular, diabetes, oncology, rare disease and vaccines across Latin America. Comparable as a broad-portfolio competitor in the same therapeutic categories Adium addresses, though at materially larger scale and with proprietary global R&D.
- Novartis AG: Novartis is a global branded pharmaceutical incumbent with an established commercial presence across Latin America, overlapping with Adium in cardiology, oncology, neurology and immunology therapeutic areas. It competes broadly but is not specialty-focused on the LatAm mid-tier market Adium targets.
Direct peers
- Eurofarma Laboratórios: Eurofarma is a Brazilian privately held pharmaceutical company with manufacturing operations across Latin America and a portfolio spanning multiple therapeutic areas including specialty, generics and OTC — directly comparable to Adium México in scale, LatAm geographic footprint, and broad-therapeutic-area pharmaceutical commercialization model.
- Laboratorios Bagó: Bagó is an Argentine-founded multinational pharmaceutical group with operations across Latin America, manufacturing branded specialty and OTC products. Its pan-regional LatAm manufacturing and commercial model is closely comparable to Adium's group-level footprint.
- Aché Laboratórios Farmacêuticos: Aché is a top-five Brazilian pharmaceutical company with branded generics, prescription, and OTC products plus a meaningful oncology franchise. Like Adium, Aché operates manufacturing in multiple Latin American countries with multi-therapeutic-area coverage and is a comparable regional scale player.
- EMS Pharma: EMS is one of the largest Brazilian pharmaceutical manufacturers with leading market share in Brazil and a broad generics-plus-branded portfolio. It is a direct competitor to Adium in the Latin American prescription pharmaceutical market, particularly in Brazil and cross-border specialty categories.
- Biolab Farmacêutica: Biolab is a Brazilian specialty pharmaceutical company with strong presence in cardiology, women's health and central nervous system therapeutics. Its therapeutic mix, LatAm regional focus and licensing-driven growth model closely resemble Adium's strategy.
- Siegfried Holding: Siegfried is a Swiss pharmaceutical manufacturer specializing in contract development and manufacturing for branded and generic drugs globally, including Latin America. Comparable to Adium in the manufacturing-for-license-partners and finished-dose pharmaceutical production model.
Regional players
- Laboratorios Liomont: Liomont is a Mexican pharmaceutical manufacturer of branded generics and specialty products, operating mainly in Mexico but exporting regionally. It is comparable to Adium México on therapeutic-area breadth and Mexico-centric manufacturing, though smaller in geographic reach.
- Genomma Lab Internacional: Genomma Lab is a Mexico-headquartered pharmaceutical company listed on the Mexican Stock Exchange with a portfolio spanning OTC, personal care and branded generics across Latin America. It is the most direct publicly traded Mexican pharma comparable to Adium México in therapeutic breadth and LatAm commercial footprint.
Market position
Strengths3 records
Weaknesses5 records
Competitive moat6 records
Key risks5 records
Key highlights6 records
Customer concentration
Adium México social profiles
Digital presenceAdium México compliance and trust
Trust signalCompliance2 records
Adium México financial estimates
Financial estimateRevenue estimate
Valuation estimate
Adium México leadership team
Management profileNumber of profiles
Profiles1 record
Adium México subsidiaries and ownership
Company hierarchySubsidiaries1 record
Adium México funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Adium México M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Adium México
What does Adium México do?
Adium México is a pharmaceutical laboratory that develops, manufactures, and commercializes a broad portfolio of prescription medications across 15 therapeutic areas including cardiology, diabetes, oncology, rare diseases, neurology, and gynecology. The company distributes both proprietary products and those licensed from global biotech partners to healthcare professionals and institutions in Mexico, supported by a specialized sales force, GMP-certified manufacturing, and pharmacovigilance systems aligned with international regulatory standards.
Is Adium México a public or private company?
Adium México is a private company. It is classified as corporate owned and is currently operating.
When was Adium México founded?
Adium México was founded in 1974. It employs 501 to 1,000 people.
Where is Adium México based?
Adium México is headquartered in México, Colombia, in the Latin America region.
How does Adium México make money?
Two revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are licensing and Distribution.
Who are Adium México's main competitors?
Broad incumbents on record are Sanofi and Novartis AG. Direct peers are Eurofarma Laboratórios, Laboratorios Bagó, Aché Laboratórios Farmacêuticos, EMS Pharma, Biolab Farmacêutica and Siegfried Holding. Regional players are Laboratorios Liomont and Genomma Lab Internacional.
Does Adium México have an API?
No public API is recorded for Adium México.
What industry is Adium México in?
Adium México's product category is Pharmaceutical Manufacturing. Its primary akta.pro industry code is CRAOAHAA, Prescription Pharmaceutical (Rx) Wholesale Distribution. Its NAICS code is 325412 and its SIC code is 2834.